Werner Sean 4

What Happened

• Sean Werner, Chief Technology Officer of BioLife Solutions, was granted 24,116 restricted shares (transaction code A) on 2026-02-24 as part of his 2026 compensation. No purchase price is reported (award), so no cash changed hands and no immediate market value is realized in the filing.
• The award is subject to vesting: 25% vests on the first anniversary of the grant date and the remaining 75% vests quarterly in 12 equal installments thereafter, under the BioLife Solutions 2023 Omnibus Performance Incentive Plan.

Key Details

• Transaction date: 2026-02-24; Filing date: 2026-02-26 (filed within the standard two-business-day window).
• Shares granted: 24,116 restricted shares; price: N/A (award).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Grant governed by the 2023 Omnibus Performance Incentive Plan; vests 25% at year one, then quarterly in 12 equal installments; granted as part of 2026 compensation.
• Transaction type: Award/Grant (code A), not a market purchase or sale.

Context

• Restricted stock awards are common executive compensation designed to retain and align management; these shares are subject to vesting and generally are not immediately tradable until vested.
• Awards are not direct buy/sell signals about the insider’s market view — they reflect compensation decisions by the company.